© 1983 J. Pharm. Pharmacol.

Interaction of leukotriene D_4 and histamine on bronchomotor tone, in the guinea-pig

A. G. STEWART^{*}, D. C. THOMPSON, M. R. FENNESSY, Department of Pharmacology, University of Melbourne, Parkville, Victoria, 3052, Australia

Leukotriene D_4 (LTD₄) has been identified as one of the major components of SRS-A (Morris et al 1980). In the guinea-pig, LTD₄ produces bronchoconstriction, increases in vascular permeability and variable cardiovascular effects dependent on the state of consciousness (Drazen et al 1980). Its release during immediate hypersensitivity reactions suggests it has a role in asthma. Since LTD₄ is released concomitantly with other bronchoconstrictor mediators (e.g. histamine, bradykinin), the possibility of mutual potentiation of bronchoconstrictor actions arises. We have investigated a possible interaction between LTD₄ and histamine in both isolated and intact airway preparations of the guinea-pig.

Methods

Guinea-pigs of either sex (Dunkin Hartley) (350– 450 g), were killed by a blow to the head, and tracheae and lungs rapidly removed. Isolated tracheal and parenchymal lung strips were mounted in 25 ml organ baths in Krebs solution maintained at 37 °C and gassed with 5% CO_2 in O_2 .

Tracheal strips (Emmerson & Mackay 1979) were mounted under a load of 0.5 g, equilibrated for 60 min and then exposed to a supramaximal concentration of acetylcholine (ACh 0.5 mм). Parenchymal lung strips (Drazen & Schneider 1978) were mounted under a load of 0.5 g, equilibrated for 30 min and then exposed to ACh (0.5 mM). Responses to histamine are expressed as a % of the response to ACh. Concentration-response relationships to histamine were obtained by cumulative addition of histamine to the organ bath (van Rossum 1963). To investigate the effect of LTD_4 on histamine concentration-response curves, the concentration of LTD₄ was cumulatively increased from 10 рм until a response was just produced. Histamine concentrationresponse curves were then constructed in both control and LTD₄-treated preparations.

Guinea-pigs of either sex (350–450 g) were anaesthetized with a mixture of 25% w/v urethane and 0.3% w/v sodium pentobarbitone (5 ml kg⁻¹). A tracheal cannula, for artificial ventilation, was then inserted. The respiration pump (Palmer) was adjusted to deliver 0.7 ml of air/100 g body weight per stroke at a stroke rate of 60 strokes min⁻¹. Intratracheal pressure (ITP) (McCulloch et al 1967) was measured by connecting a

* Correspondence.

T-junction on the tracheal cannula to a Druck pressure transducer (PDCR 75). Following surgical preparation, gallamine (4 mg kg⁻¹, i.v.) was administered to prevent spontaneous respiratory movements. All drugs were injected in 0.2 ml 0.9% NaCl (saline) via a cannula inserted in the left jugular vein; and flushed in with a further 0.2 ml saline. Potentiation of histamine-induced increases in ITP were determined by reference to bracket-control histamine reponses elicited 6 min before and 6 min after the test response to histamine following LTD₄ pretreatment.

The nominal concentration of LTD_4 (as supplied by Merck Frosst, Canada), was confirmed by absorbance at 280 nm. The LTD_4 had an absorption maximum at 280 nm, with shoulders at 290 and 272 nm, closely corresponding to those previously published for LTD_4 (Lewis et al 1980a). In addition, reverse phase h.p.l.c. (Waters, C₁₈ µBondapak), using 60:40 methanol–0.1% acetic acid pH 5.6 at a flow rate of 1 ml min⁻¹, showed a single major peak which eluted at 12.5 min with a minor peak at 13.75 min (approximately 8%) which may have been 11-trans LTD₄ (Lewis et al 1980b).

The drugs used were gallamine triethiodide (May & Baker); histamine diphosphate (Sigma); sodium pentobarbitone (Abbott), acetylcholine perchlorate, urethane (BDH Chemicals).

Results

The threshold constrictor concentration of LTD₄ in the parenchymal lung strips (0.19 ± 0.03 nM) was 10-fold lower than that in the isolated trachea (1.94 ± 0.48 nM). LTD₄, in threshold constrictor concentrations, had no effect on either the EC50 or maximum response to histamine (P > 0.05, unpaired *t*-test) in parenchymal or tracheal strips (Table 1).

LTD₄ (0.5 µg kg⁻¹, i.v.) administered 20 s before histamine (4 or 8 µg kg⁻¹, i.v.) significantly potentiated (P < 0.05, paired *t*-test) the responses to these doses of histamine (Table 2). There was a small bronchoconstrictor response to LTD₄ alone (P < 0.05, paired *t*-test) which, when superimposed on that to histamine alone, does not account for the increase in ITP when these bronchoconstrictors were administered 20 s apart.

Discussion

LTD₄ potentiates the bronchoconstrictor action of histamine in-vivo. However, neither the potency of histamine nor its maximal response was altered by Table 1. The effect of threshold constrictor concentrations of leukotriene D₄ (LTD₄) on histamine concentrationresponse curves in isolated airways smooth muscle preparations of the guinea-pig. Responses are expressed as % of the response to acetylcholine (0.5 mM).

Tissue	Concentration of LTD ₄ (µм)	EC50 for histamine (µм)	Maximum response to histamine
Trachea		3.6 ± 0.7	131.9 ± 10.3
	1.94 ± 0.48	3.5 ± 0.3	126.4 ± 5.5
Parenchyma	_	0.9 ± 0.1	223.3 ± 22.5
•	0.19 ± 0.03	1.2 ± 0.4	226.4 ± 27.7

Values are mean ± s.e. of 7 guinea-pigs.

EC50 is the concentration which produced half the maximal response.

Table 2. The effect of LTD₄ (0.5 μ g kg⁻¹, i.v.) on the increase in intratracheal pressure (ITP) produced by histamine (4 or 8 μ g kg⁻¹) in an esthetized guinea-pigs. LTD₄ or saline was administered 20 s before the histamine. ITP was measured when the responses were maximal.

Pretreatment	Treatment	ITP (cm H ₂ O)
-		8.03 ± 0.40 (resting ITP)
LTD ₄ 0.5 µg kg ⁻¹ Saline 0.2 ml LTD ₄ 0.5 µg kg ⁻¹ Saline 0.2 ml LTD ₄ 0.5 µg kg ⁻¹	histamine 4 µg kg ⁻¹ histamine 4 µg kg ⁻¹ histamine 8 µg kg ⁻¹ histamine 8 µg kg ⁻¹	$\begin{array}{c} 9.00 \pm 0.37^{*} \\ 11.17 \pm 2.66^{*} \\ 19.83 \pm 4.69^{*}.*^{*} \\ 18.75 \pm 3.27^{*} \\ 28.71 \pm 2.21^{*}.*^{*} \end{array}$

Values are mean \pm s.e. of 6–9 guinea-pigs.

* P < 0.05, paired *i*-test compared to resting ITP. ** P < 0.05, paired *i*-test, compared to saline pretreatment for the same dose of histamine.

 LTD_4 in either tracheal strips (central airways) or parenchymal strips (peripheral airways). Thus there appears to be no direct interaction between LTD₄ and histamine on the smooth muscle cell. The potency of LTD₄, both in-vitro and in-vivo, observed in this study was less than that obtained by Drazen et al (1980). In view of this, spectral data and the elution profile of LTD_4 on reverse phase h.p.l.c. were obtained and confirmed both the concentration and chemical nature of the material used as LTD₄ (see Methods). Possible reasons for this difference in observed potencies include genetic and dietary differences with respect to guineapigs and sensitivity of measurements of bronchomotor tone.

Both the importance and mechanism of the LTD₄induced potentiation of the bronchoconstrictor action of histamine are yet to be established. However, LTD₄ has been proposed as a primary mediator of asthma (Dahlen et al 1980) and, furthermore, bronchial hyperreactivity appears to be invariably associated with this disease (Nadel 1980). As such, the data reported here appear consistent with the working hypothesis that LTD_4 may be a mediator of bronchial hyper-reactivity.

We would like to thank Dr J. Rokach (Merck Frosst, Canada, Inc.) for generous gifts of leukotriene D₄.

REFERENCES

- Dahlen, S., Hedqvist, P., Hammarström, S., Samuelsson, B. (1980) Nature (London) 288: 484–486
- Drazen, J. M., Austen, K. F., Lewis, R. A., Clark, D. A., Goto, G., Marfat, A., Corey, E. J. (1980) Proc. Natl. Acad. Sci. 77: 4354-4358
- Drazen, J. M., Schneider, M. W. (1978) J. Clin. Invest. 61: 1441-1447
- Emmerson, J., Mackay, D. (1979) J. Pharm. Pharmacol. 31: 798
- Lewis, R. A., Austen, K. F., Drazen, J. M., Clark, D. A., Marfat, A., Corey, E. J. (1980a) Proc. Natl. Acad. Sci. 77: 3710-3714
- Lewis, R. A., Drazen, J. M., Austen, K. F., Clark, D. A., Corey, E. J. (1980b) Biochem. Biophys. Res. Commun. 96: 271-277
- McCulloch, M. W., Proctor, C., Rand, M. J. (1967) Eur. J. Pharmacol. 2: 214-223
- Morris, H. R., Taylor, C. W., Piper, P. J., Tippins, J. R. (1980) Nature (London) 285: 104-106
- Nadel, J. A. (1980) Prog. Respir. Dis. 14: 1-8
- van Rossum, J. M. (1963) Arch. Int. Pharmacodyn. Thér. 143: 299-330